1. Home
  2. BVS vs MNKD Comparison

BVS vs MNKD Comparison

Compare BVS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$14.37

Market Cap

982.2M

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.04

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
MNKD
Founded
2011
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
982.2M
1.2B
IPO Year
2016
2004

Fundamental Metrics

Financial Performance
Metric
BVS
MNKD
Price
$14.37
$4.04
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$14.00
$8.69
AVG Volume (30 Days)
740.9K
3.8M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
163.46
N/A
EPS
0.52
N/A
Revenue
$568,087,000.00
$348,966,000.00
Revenue This Year
$7.52
$35.81
Revenue Next Year
$7.06
$11.89
P/E Ratio
$26.29
N/A
Revenue Growth
N/A
22.23
52 Week Low
$6.26
$2.23
52 Week High
$15.89
$6.51

Technical Indicators

Market Signals
Indicator
BVS
MNKD
Relative Strength Index (RSI) 60.52 51.16
Support Level $8.21 $3.74
Resistance Level $14.92 $4.23
Average True Range (ATR) 0.51 0.16
MACD -0.13 -0.01
Stochastic Oscillator 64.19 50.70

Price Performance

Historical Comparison
BVS
MNKD

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: